• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Anika’s Monovisc therapy gets green light in Australia

October 17, 2017 By Sarah Faulkner

Anika TherapeuticsAnika Therapeutics (NSDQ:ANIK) said yesterday that regulatory authorities in Australia approved the company’s single injection viscosupplement, Monovisc, for the treatment of pain associated with osteoarthritis of the synovial joints.

This latest regulatory win means that Monovisc is commercially available in more than twenty countries, including the U.S. and Canada. The Bedford, Mass.-based company said it plans to move into additional international markets next year with its therapy for hip and knee pain.

“The Asia-Pacific region presents an important growth opportunity for our global orthobiologics franchise, and we’re excited to bring Monovisc to patients in Australia and New Zealand,” CEO Charles Sherwood said in prepared remarks. “With this approval, Monovisc is poised to become the most widely available single-injection viscosupplement in the world and will be a key driver in growing global market share.”

Anika has partnered exclusively with Surgical Specialties to market Monovisc in Australia and New Zealand, the company said.

In July, Anika named medtech veteran Joseph Darling as president, taking over the role fromSherwood. The chief exec plans to stay in the corner office as he transitions the role of president to Darling.

Previously, Darling worked as an executive in privately-held orthopedic companies. He has also held senior level executive roles at ConMed Corp. and Smith & Nephew.

See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.

Filed Under: Drug-Device Combinations, Featured, Orthopedics, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Anika Therapeutics Inc.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS